Prothena Corp Public Ltd Co
PRTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001559053
In the last 90 days, Prothena Corp Public Ltd Co insiders filed 10 open-market purchases and 0 sales; 189 institutions reported holding it in 13F filings for Q2 2026, worth $462.7M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:52 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $244.1M (2520.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Feb 20, 2025 | Jan 8, 2024 | Feb 23, 2023 | Feb 17, 2022 |
| Revenue | $9.68M | $135.2M | $91.4M | $53.9M | $200.6M |
| Operating expenses | $224.3M | $289.7M | $282.4M | $185.5M | $128.6M |
| Research and development | $134.9M | $222.5M | $220.6M | $135.6M | $82.3M |
| Selling, general and administrative | $59.4M | $67.2M | $61.8M | $49.9M | $46.3M |
| Operating income | -$214.6M | -$154.6M | -$191.0M | -$131.6M | $72.0M |
| Income tax | $43.3M | -$6.62M | -$13.5M | -$8.66M | $4.95M |
| Net income | -$244.1M | -$122.3M | -$147.0M | -$116.9M | $67.0M |
| EPS, basic | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.51 |
| EPS, diluted | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 |
| Weighted shares, basic | 53.8M | 53.8M | 53.2M | 47.4M | 44.2M |
| Weighted shares, diluted | 53.8M | 53.8M | 53.2M | 47.4M | 48.5M |
| Margins and growth | |||||
| Operating margin | -2216.4% | -114.4% | -209.1% | -244.1% | 35.9% |
| Net margin | -2520.6% | -90.5% | -160.9% | -217.0% | 33.4% |
| Revenue growth, year over year | −92.8% | +47.9% | +69.5% | −73.1% | +23,414.3% |
| Net income growth, year over year | – | – | – | −274.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Feb 20, 2025 | Jan 8, 2024 | Feb 23, 2023 | Feb 17, 2022 |
| Cash and equivalents | $307.5M | $471.4M | $618.8M | $710.4M | $579.1M |
| Accounts receivable | – | $0 | $5.16M | – | $0 |
| Total current assets | $315.2M | $485.4M | $639.3M | $719.1M | $584.8M |
| Property, plant and equipment | $2.14M | $3.08M | $3.84M | $1.73M | $2.01M |
| Total assets | $326.8M | $547.1M | $696.4M | $758.0M | $609.4M |
| Accounts payable | $5.88M | $7.77M | $25.4M | $9.27M | $3.69M |
| Total current liabilities | $40.8M | $48.5M | $56.9M | $50.1M | $33.5M |
| Total liabilities | $46.3M | $60.2M | $135.0M | $136.0M | $143.3M |
| Shareholders' equity | $280.5M | $486.9M | $561.4M | $622.0M | $466.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Feb 20, 2025 | Jan 8, 2024 | Feb 23, 2023 | Feb 17, 2022 |
| Operating cash flow | -$163.6M | -$150.1M | -$133.9M | -$108.8M | $92.6M |
| Depreciation and amortization | $895.0K | $893.0K | $928.0K | $744.0K | $1.11M |
| Stock-based compensation | $37.6M | $46.0M | $40.9M | $31.3M | $24.7M |
| Investing cash flow | -$138.0K | -$298.0K | -$2.77M | -$464.0K | -$575.0K |
| Financing cash flow | -$139.0K | $1.55M | $45.1M | $241.5M | $190.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 388.7% | 34.0% | 44.8% | 58.1% | 12.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 51.3M | −4.6% | SEC |
| Jul 30, 2026 | 51.3M | −4.6% | SEC |
| Apr 30, 2026 | 52.4M | −2.7% | SEC |
| Feb 20, 2026 | 53.8M | 0.0% | SEC |
| Oct 31, 2025 | 53.8M | 0.0% | SEC |
| Jul 25, 2025 | 53.8M | +0.1% | SEC |
| May 1, 2025 | 53.8M | +0.1% | SEC |
| Feb 20, 2025 | 53.8M | +0.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.